Compare AJANTA PHARMA with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ABBOTT INDIA AJANTA PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 22.8 55.0 41.4% View Chart
P/BV x 3.9 13.3 29.5% View Chart
Dividend Yield % 0.9 0.5 173.5%  

Financials

 AJANTA PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
ABBOTT INDIA
Mar-19
AJANTA PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,4228,834 16.1%   
Low Rs8985,458 16.4%   
Sales per share (Unadj.) Rs233.51,731.1 13.5%  
Earnings per share (Unadj.) Rs44.0211.9 20.7%  
Cash flow per share (Unadj.) Rs52.2219.9 23.7%  
Dividends per share (Unadj.) Rs9.0065.00 13.8%  
Dividend yield (eoy) %0.80.9 85.3%  
Book value per share (Unadj.) Rs255.1945.2 27.0%  
Shares outstanding (eoy) m88.0221.25 414.2%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.04.1 120.3%   
Avg P/E ratio x26.433.7 78.2%  
P/CF ratio (eoy) x22.232.5 68.4%  
Price / Book Value ratio x4.57.6 60.1%  
Dividend payout %20.530.7 66.7%   
Avg Mkt Cap Rs m102,081151,848 67.2%   
No. of employees `0006.83.5 195.1%   
Total wages/salary Rs m4,3074,356 98.9%   
Avg. sales/employee Rs Th3,022.610,555.5 28.6%   
Avg. wages/employee Rs Th633.41,249.9 50.7%   
Avg. net profit/employee Rs Th569.11,292.2 44.0%   
INCOME DATA
Net Sales Rs m20,55436,786 55.9%  
Other income Rs m2111,133 18.6%   
Total revenues Rs m20,76537,919 54.8%   
Gross profit Rs m5,6646,047 93.7%  
Depreciation Rs m721169 426.0%   
Interest Rs m1223 51.6%   
Profit before tax Rs m5,1436,989 73.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2732,485 51.2%   
Profit after tax Rs m3,8704,503 85.9%  
Gross profit margin %27.616.4 167.6%  
Effective tax rate %24.835.6 69.6%   
Net profit margin %18.812.2 153.8%  
BALANCE SHEET DATA
Current assets Rs m11,81227,610 42.8%   
Current liabilities Rs m3,7768,569 44.1%   
Net working cap to sales %39.151.8 75.5%  
Current ratio x3.13.2 97.1%  
Inventory Days Days7760 128.5%  
Debtors Days Days8227 297.8%  
Net fixed assets Rs m14,3981,057 1,362.3%   
Share capital Rs m175213 82.5%   
"Free" reserves Rs m22,27719,873 112.1%   
Net worth Rs m22,45220,086 111.8%   
Long term debt Rs m70-   
Total assets Rs m26,96229,409 91.7%  
Interest coverage x444.3311.6 142.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.81.3 60.9%   
Return on assets %14.415.4 93.5%  
Return on equity %17.222.4 76.9%  
Return on capital %23.034.9 65.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,682369 2,895.1%   
Fx outflow Rs m2,1024,918 42.7%   
Net fx Rs m8,580-4,549 -188.6%   
CASH FLOW
From Operations Rs m3,7484,991 75.1%  
From Investments Rs m-2,228-2,570 86.7%  
From Financial Activity Rs m-1,475-1,428 103.3%  
Net Cashflow Rs m45993 4.6%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 7.9 19.6%  
FIIs % 7.6 0.1 7,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.1 99.4%  
Shareholders   20,968 18,270 114.8%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Why is Sensex at a Record High When Economy is in Trouble?(Podcast)

In today's episode, I talk about all the major moves of the week, including Modi government's blockbuster disinvestment, developments in the telecom sector.

Related Views on News

PFIZER at All Time High; BSE HEALTHCARE Index Up 0.7% (Market Updates)

Nov 22, 2019 | Updated on Nov 22, 2019

PFIZER share price has hit an all time high at Rs 4,199 (up 1.7%). The BSE HEALTHCARE Index is up by 0.7%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 1.7%) and ABBOTT INDIA (up 0.6%). The top losers include DR. REDDYS LAB (down 0.1%) and ALKEM LABORATORIES (down 0.3%).

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 22, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - ALEMBIC LTD COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS